Trials / Completed
CompletedNCT01270828
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia
A Phase 3 Double-blind, Randomized, Placebo-controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia (Protocol A0081224)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 806 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to explore the safety and efficacy of a new once a day pregabalin formulation versus placebo for patients with post herpetic neuralgia (Shingles)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin | Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks |
| DRUG | placebo | Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2014-09-01
- Completion
- 2014-11-01
- First posted
- 2011-01-05
- Last updated
- 2021-01-28
- Results posted
- 2016-01-13
Locations
146 sites across 17 countries: United States, Bulgaria, Colombia, Croatia, Czechia, Denmark, Germany, Hong Kong, India, Poland, Russia, Serbia, Slovakia, South Africa, Sweden, Taiwan, Ukraine
Source: ClinicalTrials.gov record NCT01270828. Inclusion in this directory is not an endorsement.